Affordable Access

Access to the full text

The role of specific biomarkers, as predictors of post-operative complications following flexible ureterorenoscopy (FURS), for the treatment of kidney stones: a single-centre observational clinical pilot-study in 37 patients

Authors
  • Hughes, Stephen Fôn1, 1
  • Moyes, Alyson Jayne1, 2, 3
  • Lamb, Rebecca May1, 3
  • Ella-tongwiis, Peter1, 1
  • Bell, Christopher1, 4
  • Moussa, Ahmed1, 4
  • Shergill, Iqbal1, 1, 4
  • 1 Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital, Wrexham, Wales, UK , Wrexham (United Kingdom)
  • 2 Bangor University, Bangor, Wales, UK , Bangor (United Kingdom)
  • 3 University of Chester, Chester, UK , Chester (United Kingdom)
  • 4 BCUHB Wrexham Maelor Hospital, Wrexham, Wales, UK , Wrexham (United Kingdom)
Type
Published Article
Journal
BMC Urology
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Aug 14, 2020
Volume
20
Issue
1
Identifiers
DOI: 10.1186/s12894-020-00693-4
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundThe number of patients diagnosed and subsequently treated for kidney stones is increasing, and as such the number of post-operative complications is likely to increase. At present, little is known about the role of specific biomarkers, following flexible ureterorenoscopy (FURS) for the surgical treatment of kidney stones. The main aim of the study was to evaluate the role of kidney and infection biomarkers, in patients undergoing FURS.MethodsIncluded were 37 patients (24 males, 13 females), who underwent elective FURS, for the treatment of kidney stones. Venous blood samples were collected from each patient: pre-operatively, and at 30 min, 2 and 4 h post-operatively. Changes to kidney (NGAL, Cystatin-C) and infection (MPO, PCT) biomarkers was quantified by means of ELISA, Biomerieux mini-vidas and Konelab 20 analysers.ResultsFour patients developed post-operative complications (3 - UTIs with urinary retention, 1 - urosepsis. NGAL concentration increased significantly following FURS (p = 0.034). Although no significant changes were seen in Cystatin C, MPO and PCT (p ≥ 0.05) some key clinical observation were noted. Limiting factors for this study were the small number of patients recruited and restriction in blood sampling beyond 4 h.ConclusionsAlthough not confirmative, changes seen to biomarkers such as Cystatin C, NGAL and MPO in our observational clinical pilot-study may warrant further investigation, involving larger cohorts, to fully understand the role of these biomarkers and their potential association with post-operative complications which can develop following FURS.

Report this publication

Statistics

Seen <100 times